Suzhou Sanegene Bio Receives NMPA Approval for Clinical Trial of Antihypertensive siRNA Drug
Suzhou Sanegene Bio Inc., a leading RNAi specialist with research and development centers in both...
RNAi / ASO
AusperBio’s AHB-137 Antiviral Candidate on Path to Breakthrough Designation for Chronic Hepatitis B in China
AusperBio, a sino-American developer specializing in liver therapies, has announced that its drug candidate AHB-137...
Sirnaomics’ STP122G Achieves Phase I Milestone with Positive Interim Data for Anticoagulation Treatment
Sirnaomics Ltd (HKG: 2257) has announced the completion of the Phase I second sequence for...
Chia Tai Tianqing’s TQA3038 siRNA Drug Completes Phase I Clinical Trial for Chronic Hepatitis B
Chia Tai Tianqing has announced the successful completion of a Phase I clinical study for...
Sirnaomics Receives FDA Feedback on STP705 Development Plan for isSCC Treatment
Sirnaomics Ltd (HKG: 2257), a leading biopharmaceutical company focused on the discovery and development of...
Arnatar Therapeutics Secures $50 Million in Series A Funding to Expand into China
US-based biotechnology company Arnatar Therapeutics has successfully closed a $50 million Series A financing round,...
Shanghai Medicilon Forms Strategic Partnerships with Binhui Biopharmaceutical and Innoforce Pharmaceuticals
Shanghai Medicilon Biomedical Co., Ltd (SHA: 688202), a prominent Chinese biotech firm, has entered into...
HitGen Secures CDE Approval for Lipisense IND Filing, Advancing Development for Dyslipidemia Treatment
HitGen Inc., (SHA: 688222) a China-based pharmaceutical company, has announced that the Investigational New Drug...
AstraZeneca Launches Phase I Trial for siRNA Therapy in Collaboration with Silence Therapeutics
AstraZeneca (AZ; NASDAQ: AZN) has commenced a Phase I trial for a short interfering RNA...
Visirna Therapeutics Completes Enrollment in Phase III Study for FCS Drug VSA001
Visirna Therapeutics, a Shanghai-based biopharmaceutical company, has announced the completion of patient enrollment in a...
Novartis Strikes Deal with Argo Biopharma for Global Rights to siRNA Drug Candidates
Argo Biopharma, a Shanghai-based developer of small interfering RNA (siRNA) drugs, has secured a licensing...
Boehringer Ingelheim Partners with Suzhou Ribo Life Science to Develop siRNA Therapies for NASH/MASH
Boehringer Ingelheim (BI), a Germany-headquartered pharmaceutical company, has entered into a collaboration agreement with Suzhou...
Innovent Biologics Partners with Sanegene Bio USA to Develop Hypertension Drug
China-based Innovent Biologics (HKG: 1801) has entered into a partnership with Sanegene Bio USA Inc....
Suzhou Ribo Life Science Strikes Deal with Qilu Pharmaceutical for PCSK9 siRNA Drug
Suzhou Ribo Life Science Co., Ltd, a specialist in small interfering RNA (siRNA) drugs based...
Sino Biopharmaceutical Initiates Phase I Trial for Hepatitis B siRNA Drug TQA3038
Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company based in China, has announced the...
SanegeneBio Secures Over USD 80 Million in Series A+ Funding to Advance RNAi Therapeutics
SanegeneBio, a Suzhou-based developer of RNA interference (RNAi) therapeutics, has successfully raised over USD 80...
BMS and Avidity Biosciences Join Forces on $2.2 Billion Cardiology Antibody Oligonucleotide Conjugate Deal
Bristol Myers Squibb (BMS, NYSE: BMY) has announced a strategic partnership with Avidity Biosciences (NASDAQ:...
SanegeneBio Partners with Huadong Medicine to Develop RNAi Therapeutics for Metabolic Diseases
Suzhou-based RNA interference (RNAi) therapeutics developer SanegeneBio has entered into a partnership with compatriot firm...
XtalPi Inc. and CK Life Sciences Expand Partnership to Develop AI-Powered Cancer Diagnostics
Sino-US artificial intelligence (AI) firm XtalPi (QuantumPharm, HKG: 2228) has announced a strategic partnership agreement...
Sirnaomics’ STP705 Demonstrates Positive Results in Phase I Focal Fat Reduction Study
Sirnaomics Ltd (HKG: 2257) has announced positive safety and efficacy results from a Phase I...